Form 4: BioXcel Therapeutics CFO Richard Steinhart Reports Routine Vesting of Restricted Stock Units

BioXcel Therapeutics, Inc.'s Chief Financial Officer, Richard I. Steinhart, reported the acquisition of 68 shares of common stock through the routine vesting of Restricted Stock Units on June 14 and June 15, 2025, increasing his direct beneficial ownership.

Summary

• Richard I. Steinhart, Chief Financial Officer of BioXcel Therapeutics, Inc. (BTAI), reported changes in his beneficial ownership of the company's common stock.
• On June 14, 2025, Mr. Steinhart acquired 33 shares of common stock through the vesting of Restricted Stock Units (RSUs). Following this transaction, he directly beneficially owned 1,406 shares.
• On June 15, 2025, he acquired an additional 35 shares of common stock, also through the vesting of RSUs. This brought his direct beneficial ownership to 1,441 shares.
• These transactions were executed under a Rule 10b5-1(c) plan, indicating a pre-arranged schedule for the acquisition of equity securities.
• Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock.
• The RSUs involved in the June 14, 2025 transaction were part of a grant of 521 RSUs on March 14, 2022, which vest over time, subject to continuous employment.
• The RSUs involved in the June 15, 2025 transaction were part of a grant of 562 RSUs on March 15, 2023, also vesting over time under similar conditions.

Sentiment

Score: 6

Explanation: The document reports routine, expected insider transactions (RSU vesting) which are generally neutral to slightly positive as they indicate continued executive ownership and compensation. There are no negative or highly positive surprises.

Positives

• The CFO's increased direct beneficial ownership of company stock, albeit small, aligns his interests with shareholders.
• The transactions were conducted under a Rule 10b5-1(c) plan, indicating they were pre-scheduled and non-discretionary, which is a standard practice for executive equity compensation and can reduce concerns about opportunistic insider trading.

Future Outlook

This Form 4 filing reports past transactions related to RSU vesting and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report (Form 4) for a biotechnology company. It reflects standard compensation practices (RSU vesting) for executives and does not provide specific insights into broader industry trends or competitive landscape beyond the fact that BioXcel Therapeutics, Inc. is a publicly traded company with executive compensation structures common in the industry.

Comparison to Industry Standards

• The vesting of Restricted Stock Units (RSUs) as a form of executive compensation is a common practice across the biotechnology and pharmaceutical industries, aligning executive incentives with long-term shareholder value.
• Companies like Moderna, Pfizer, and Biogen frequently utilize similar equity-based compensation plans for their executives.
• The specific number of shares vested (68 shares in total across two days) is consistent with periodic vesting schedules rather not large, discretionary purchases or sales, which is typical for routine RSU vesting.
• The use of a Rule 10b5-1 plan for these transactions is also a standard corporate governance practice to mitigate concerns about insider trading.

Stakeholder Impact

• Shareholders: The increase in the CFO's direct beneficial ownership, albeit small, aligns his interests with shareholders.
• Employees: The RSU vesting is part of executive compensation, which is a standard practice for retaining and incentivizing key personnel.

Key Dates

Recommendation

Keywords

BioXcel Therapeutics, BTAI, Richard I. Steinhart, Chief Financial Officer, CFO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Ownership, Rule 10b5-1